Skip to main content
Vor Biopharma Inc. logo

Vor Biopharma Inc. — Investor Relations & Filings

Ticker · VOR ISIN · US9290331084 US Professional, scientific and technical activities
Open in API
Filings indexed 406 across all filing types
Latest filing 2023-03-23 Share Issue/Capital Cha…
Country US United States of America
Listing US VOR

About Vor Biopharma Inc.

https://www.vorbio.com/

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing treatments for autoimmune diseases. The company is committed to advancing medicines that target the fundamental drivers of autoimmunity, aiming to move beyond symptom control. Its lead candidate, telitacicept, is designed to silence the signals that allow harmful immune cells to survive. The company's objective is to deliver safer, longer-lasting therapies that address the source of autoimmune conditions.

Recent filings

Filing Released Lang Actions
S-8
Share Issue/Capital Change Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the U.S. Securities and Exchange Commission. It registers additional shares of common stock under employee benefit plans such as the 2021 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan. The document includes legal and procedural information related to the registration of securities for employee compensation plans, not financial results or management commentary. Form S-8 is a registration statement for securities issued under employee benefit plans and is not an earnings release, annual report, or other financial report. It is a capital market filing related to share issuance under employee plans, which fits the category of Share Issue/Capital Change (SHA). The document is lengthy and substantive, not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is SHA with high confidence.
2023-03-23 English
10-K
Annual Report FY 2022
2023-03-23 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-03 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-03 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on a clinical update and a press release about additional clinical data from a Phase 1/2a study. There are no financial statements or detailed financial data included. The document includes a press release as an exhibit and states that the information is furnished under Item 7.01 Regulation FD Disclosure, which is typically used for material news announcements. The document does not contain quarterly or annual financial results, management discussion, or audit information. It is not a full financial report but rather a regulatory announcement of a clinical update and press release. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-02-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.